CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CareDx, Inc. (Nasdaq: CDNA), a precision medicine company focused on transplant healthcare solutions, has granted restricted stock units (RSUs) to 14 new employees as an inducement for employment. A total of 44,000 shares of common stock were awarded under the company's 2019 Inducement Equity Incentive Plan, approved under Nasdaq Listing Rule 5635(c)(4).
The RSUs have varying vesting schedules:
- 9,000 shares vest over four years (25% after one year, then annually)
- 14,000 shares vest over four years (25% after one year, then quarterly)
- 18,000 shares vest over three years (33.33% after one year, then quarterly)
- 2,000 shares vest over two years (50% annually)
- 1,000 shares vest over two years (50% after one year, then quarterly)
All grants are subject to continued service through each vesting date.
CareDx, Inc. (Nasdaq: CDNA), un'azienda di medicina di precisione focalizzata sulle soluzioni per la salute dei trapianti, ha concesso unità di azioni riservate (RSU) a 14 nuovi dipendenti come incentivo per l'assunzione. Un totale di 44.000 azioni ordinarie sono state assegnate nell'ambito del Piano di Incentivazione azionaria per Induzione 2019 dell'azienda, approvato secondo la Regola di quotazione Nasdaq 5635(c)(4).
Le RSU hanno diverse tempistiche di maturazione:
- 9.000 azioni maturano in quattro anni (25% dopo un anno, poi annualmente)
- 14.000 azioni maturano in quattro anni (25% dopo un anno, poi trimestralmente)
- 18.000 azioni maturano in tre anni (33,33% dopo un anno, poi trimestralmente)
- 2.000 azioni maturano in due anni (50% annualmente)
- 1.000 azioni maturano in due anni (50% dopo un anno, poi trimestralmente)
Tutti i contratti sono soggetti a continua prestazione di servizio fino a ciascuna data di maturazione.
CareDx, Inc. (Nasdaq: CDNA), una empresa de medicina de precisión centrada en soluciones de atención médica para trasplantes, ha otorgado unidades restringidas de acciones (RSU) a 14 nuevos empleados como incentivo para el empleo. Se otorgaron un total de 44,000 acciones ordinarias bajo el Plan de Incentivo de Capital por Inducción 2019 de la empresa, aprobado bajo la Regla de Cotización Nasdaq 5635(c)(4).
Las RSU tienen diferentes cronogramas de adquisición:
- 9,000 acciones se adquieren en cuatro años (25% después de un año, luego anualmente)
- 14,000 acciones se adquieren en cuatro años (25% después de un año, luego trimestralmente)
- 18,000 acciones se adquieren en tres años (33.33% después de un año, luego trimestralmente)
- 2,000 acciones se adquieren en dos años (50% anualmente)
- 1,000 acciones se adquieren en dos años (50% después de un año, luego trimestralmente)
Todos los otorgamientos están sujetos a la continuación del servicio hasta cada fecha de adquisición.
CareDx, Inc. (Nasdaq: CDNA)은 이식 의료 솔루션에 중점을 둔 정밀의료 회사로, 14명의 신입 직원에게 고용 유인을 위한 제한 주식 단위(RSU)를 부여했습니다. 총 44,000주의 보통주가 회사의 2019년 인센티브 자본 계획에 따라 수여되었으며, 이 계획은 Nasdaq 상장 규정 5635(c)(4)에 따라 승인되었습니다.
RSU의 분배 일정은 다음과 같습니다:
- 9,000주는 4년 동안 배분되며 (1년 후 25%, 그 후 매년)
- 14,000주는 4년 동안 배분되며 (1년 후 25%, 그 후 분기별)
- 18,000주는 3년 동안 배분되며 (1년 후 33.33%, 그 후 분기별)
- 2,000주는 2년 동안 배분되며 (연간 50%)
- 1,000주는 2년 동안 배분되며 (1년 후 50%, 그 후 분기별)
모든 부여는 각 배분일 기준으로 계속 서비스해야 합니다.
CareDx, Inc. (Nasdaq: CDNA), une entreprise de médecine de précision axée sur les solutions de santé pour les greffes, a accordé des unités d'actions restreintes (RSU) à 14 nouveaux employés en tant qu'incitation à l'embauche. Un total de 44 000 actions ordinaires ont été attribuées dans le cadre du Plan d'Incentive en Actions pour Induction de 2019 de l'entreprise, approuvé selon la Règle de Cotation Nasdaq 5635(c)(4).
Les RSU ont des calendriers d'acquisition variés :
- 9 000 actions acquièrent leurs droits sur quatre ans (25 % après un an, puis annuellement)
- 14 000 actions acquièrent leurs droits sur quatre ans (25 % après un an, puis trimestriellement)
- 18 000 actions acquièrent leurs droits sur trois ans (33,33 % après un an, puis trimestriellement)
- 2 000 actions acquièrent leurs droits sur deux ans (50 % annuellement)
- 1 000 actions acquièrent leurs droits sur deux ans (50 % après un an, puis trimestriellement)
Tous les octrois sont soumis à la continuité du service jusqu'à chaque date d'acquisition.
CareDx, Inc. (Nasdaq: CDNA), ein Unternehmen für Präzisionsmedizin, das sich auf Lösungen im Gesundheitsbereich für Transplantationen konzentriert, hat 14 neuen Mitarbeitern beschränkte Aktieneinheiten (RSUs) als Anreiz für die Anstellung gewährt. Insgesamt wurden 44.000 Stammaktien im Rahmen des 2019 Inducement Equity Incentive Plans des Unternehmens vergeben, der gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt wurde.
Die RSUs haben unterschiedliche Vesting-Zeitpläne:
- 9.000 Aktien werden über vier Jahre fällig (25% nach einem Jahr, dann jährlich)
- 14.000 Aktien werden über vier Jahre fällig (25% nach einem Jahr, dann vierteljährlich)
- 18.000 Aktien werden über drei Jahre fällig (33,33% nach einem Jahr, dann vierteljährlich)
- 2.000 Aktien werden über zwei Jahre fällig (50% jährlich)
- 1.000 Aktien werden über zwei Jahre fällig (50% nach einem Jahr, dann vierteljährlich)
Alle Gewährungen sind an die Fortsetzung des Dienstes bis zu jedem Vesting-Datum gebunden.
- CareDx is attracting new talent with equity incentives
- The company is utilizing its 2019 Inducement Equity Incentive Plan to align employee interests with shareholders
- Potential dilution of existing shareholders due to the issuance of 44,000 new shares
RSUs for an aggregate of 9,000 shares vest over four years, with
CareDx is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About CareDx – The Transplant Company
CareDx, Inc., headquartered in
Forward Looking Statements
This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the equity grants. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by CareDx with the SEC on February 28, 2024, the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 filed by CareDx with the SEC on May 9, 2024 and the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 filed by CareDx with the SEC on July 31, 2024, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240913883690/en/
CareDx, Inc.
Media Relations
Anna Czene
818-731-2203
aczene@caredx.com
Investor Relations
Greg Chodaczek
investor@caredx.com
Source: CareDx, Inc.
FAQ
How many new employees received RSUs from CareDx (CDNA) on September 12, 2024?
What is the total number of shares granted as RSUs by CareDx (CDNA) in this announcement?
Under which plan were the RSUs granted by CareDx (CDNA)?
What are the vesting schedules for the RSUs granted by CareDx (CDNA)?
